Breaking News, Collaborations & Alliances

Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines

These vaccines are developed at Lonza’s Center of Excellence and designed to combat respiratory diseases.

By: Rachel Klemovitch

Assistant Editor

Ethris, a clinical-stage biotechnology company creating RNA therapeutics and vaccines, and Lonza entered a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery to combat respiratory diseases. Lonza will provide spray-drying and particle engineering for vaccine candidates based on Ethris’ stabilized non-immunogenic mRNA (SNIM RNA) and stabilized lipid nanoparticles (SNaP LNP) platform at its U.S. Bend site, w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters